Publications
RNAi (RNA interference)
(1) Keller, M. (2009) Nanomedicinal Delivery Approaches for Therapeutic siRNA. Intl. J. Pharm., 379(2):210-1.
(2) Keller, M. (2005) Lipidic Carriers of RNA/DNA Oligo- and Polynucleotides: What a Difference a Formulation Makes! J.Contr. Release 103, 537-540.
(3) Spagnou, S., Miller, A. D., and Keller, M. (2004) Lipidic Carriers of siRNA: Differences in the Formulation, Cellular Uptake and Delivery with Plasmid DNA. Biochemistry 43, 13348-56.
Nanomedicine/Nanotechnology/Targeted Gene Delivery
(4) Waterhouse, J. E., Harbottle, R. P., Keller, M., et al. (2005) Synthesis and application of integrin targeting lipopeptides in targeted gene delivery. Chembiochem 6, 1212-1223.
(5) Perouzel, E., Jorgensen, M. R., Keller, M., et al. (2003) Synthesis and Formulation of Neoglycolipids for the Functionalization of Liposomes and Lipoplexes. Bioconjugate Chem. 17, 884-898.
(6) Keller, M., Jorgensen, M. R., Perouzel, E., et al. (2003) Thermodynamic Aspects and Biological Profile of CDAN/DOPE and DC-Chol/DOPE Lipoplexes. Biochemistry 42, 6067-6077.
(7) Keller, M., Harbottle, R. P., Perouzel, E., et al. (2003) Nuclear Localization Sequence Templated Non-Viral Gene Delivery Vectors: Investigation of Intracellular Trafficking Events of LMD and LD Vector Systems. ChemBioChem 4, 101-113.
(8) Moritz, S., Colin, M., Keller, M., et al. (2003) Gene Transfer by Adenovirus-Mimetic Peptides in the Presence of Cationic Lipid and/or Adenovirus. Analysis of the Contribution of the Viral and Nonviral Components. Arch. of Virology 148, 1-18.
(9) Tagawa, T., Manvell, M., Brown, N., et al. (2002) Characterisation of LMD Virus-Like Nanoparticles Self-Assembled From Cationic Liposomes, Adenovirus Core Peptide Mu () and Plasmid DNA. Gene Therapy 9, 564-576.
(10) Colin, M., Moritz, S., Fontanges, P., et al. (2001) The Nuclear Pore Complex is Involved in Nuclear Transfer of Plasmid DNA Condensed with an Oligolysine-RGD Peptide Containing Nuclear Localisation Properties. Gene Therapy 8, 1643-1653.
Peptide & Protein Drugs & Methodologies
(11) Bhakoo, A., Raynes, J. G., Heal, J. R., et al. (2004) De-Novo Design of Complementary (Antisense) Peptide Mini-Receptor Inhibitor of Interleukin 18 (IL-18). Mol. Immunology 41, 1217-1224.
(12) Patiny, L., Guichou, J. F., Keller, M., et al. (2003) Synthesis and Characterization of Constrained Cyclosporin A Derivatives Containing a Pseudo-Proline Group. Tetrahedron 59, 5241-5249.
(13) Keller, M., and Miller, A. D. (2001) Access to the Inaccessible Sequence of Cpn 60.1 (195-217) by Temporary Oxazolidine Protection of Selected Amide Bonds. Bioorg. & Med. Chem. Letters 11, 857-859.
(14) Keller, M., Boissard, C., Patiny, L., et al. (2001) Pseudoproline-Containing Analogues of Morphiceptin and Endomorphin-2: Evidence for a Cis Tyr-Pro Amide Bond in the Bioactive Conformation. J. Med. Chem. 44, 3896-3903.
(15) Wittelsberger, A., Keller, M., Scarpellino, L., et al. (2000) Pseudoprolines: Targeting a Cis Conformation in a Mimetic of the gp120 V3 Loop of HIV-1. Angew. Chem.-Internat. Ed. 39, 1111-1117.
(16) Keller, M., Wöhr, T., Dumy, P., et al. (2000) Pseudoprolines in Drug Design: Direct Insertion of Pro Systems into Cyclosporin C. Chem. Eur. J. 6, 4358-4363.
(17) Rückle, T., De Lavallaz, P., Keller, M., et al. (1999) Pseudo-Prolines in Cyclic Peptides: Conformational Stabilisation of Cyclo-[Pro-Thr(Me,Mepro)-Pro]. Tetrahedron 55, 11281-11288.
(18) Mutter, M., Wöhr, T., Gioria, S., Keller, M. (1999) Pseudo-Prolines: Induction of Cis/Trans-Conformational Interconversion by Decreased Transition State Barriers. Biopolymers 51, 121-128.
Biophysics
(19) Keller, M., Sager, C., Dumy, P., et al. (1998) Enhancing the Proline Effect: Pseudo-Prolines for Tailoring Cis/Trans Isomerization. J. Am. Chem. Soc. 120, 2714-2720.
(20) Dumy, P., Keller, M., Ryan, D. E., et al. (1997) Pseudo-Prolines as a Molecular Hinge: Reversible Induction of Cis Amide Bonds Into Peptide Backbones. J. Am. Chem. Soc. 119, 918-925.
(21) Keller, M., Tagawa, T., Preuss, M., et al. (2002) Biophysical Characterization of the DNA Binding and Condensing Properties of Adenoviral Core Peptide (mu). Biochemistry 41, 652-659.
Synthetic Organic Chemistry
(22) Keller, M., Mutter, M., and Lehmann, C. (1999) Configurational and Conformational Control on Formation and Oligomerization of 2-C Mono-Arylated Pseudo-Proline Dipeptide Building Units by Aromatic Stacking Interactions. Synlett, 935-939.
(23) Keller, M., Lehmann, C., and Mutter, M. (1999) Stereocontrol During the Formation of 2-C Mono-Arylated Pseudo-Prolines by Aromatic Stacking Interaction. Tetrahedron 55, 413-422.
Book Chapters & Proceedings
(24) Keller, M., and Miller, A. D. (2005) Non-viral Gene Therapy, Springer, Tokyo.
(25) Wöhr, T., Keller, M., Guichou, J.-F., et al. (2000) in Peptides 2000 (Martinez, J., and Fehrentz, J.-A., Eds.) pp 997-998, EDK, Paris (F), Montpellier, France.
(26) Keller, M., Preuss, M., Tagawa, T., et al. (2000) in Peptides 2000 (Martinez, J., and Fehrentz, J.-A., Eds.) pp 487-488, EDK, Paris (F), Montpellier, France.
(27) Keller, M., Boissard, C., Wittelsberger, A., et al. (2000) in Proc. Internat. Chin. Pept. Symp (Fields, G. B., Tam, J. P., and Barany, G., Eds.), Kluwer, Dorderecht.
(28) Wahl, F., Dumy, P., Keller, M., et al. (1996) in Peptides 1996 (Ramage, R., and Epton, R., Eds.) pp 893-894, Edinburgh, United Kingdom.
